Charles Schwab Investment Management Inc Arcellx, Inc. Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Arcellx, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 282,010 shares of ACLX stock, worth $16.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
282,010
Previous 264,178
6.75%
Holding current value
$16.1 Million
Previous $14.7 Million
33.78%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ACLX
# of Institutions
186Shares Held
43.4MCall Options Held
73.8KPut Options Held
196K-
Perceptive Advisors LLC New York, NY3.93MShares$224 Million5.74% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.82MShares$218 Million9.96% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$214 Million18.28% of portfolio
-
Black Rock Inc. New York, NY3.07MShares$175 Million0.01% of portfolio
-
Sr One Capital Management, LP2.35MShares$134 Million54.95% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.5B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...